This is a corrigendum to: James P Curtain, Carly Adamson, Toru Kondo, Jawad Haider Butt, Akshay S Desai, Faiez Zannad, Jean L Rouleau, Luis E Rohde, Lars Kober, Inder S Anand, Dirk J van Veldhuisen, Michael R Zile, Martin P Lefkowitz, Scott D Solomon, Milton Packer, Mark C Petrie, Pardeep S Jhund, John J V McMurray, Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction, European Heart Journal, 2023;, ehac801, https://doi.org/10.1093/eurheartj/ehac801 In the originally published version of this manuscript, one of the co-author’s name is listed as Jawad Butt. The name should be listed as Jawad Haider Butt. This error has been corrected. Published by Oxford University Press on behalf of the European Society of Cardiology 2023. This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

journal article

LitStream Collection

Treatment of late paravalvular regurgitation after transcatheter aortic valve implantation: prognostic implications

Landes, Uri; Hochstadt, Aviram; Manevich, Lisa; Webb, John G; Sathananthan, Janarthanan; Sievert, Horst; Piayda, Kerstin; Leon, Martin B; Nazif, Tamim M; Blusztein, David; Hildick-Smith, David; Pavitt, Chris; Thiele, Holger; Abdel-Wahab, Mohamed; Van Mieghem, Nicolas M;

journal article

LitStream Collection

Prevention and management of paravalvular regurgitation after transcatheter aortic valve implantation

Chung, Christine J; Otto, Catherine M

2023 European Heart Journal

doi: 10.1093/eurheartj/ehad151pmid: 36891780

Graphical AbstractGraphical AbstractManagement of paravalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI). Most patients with mild PVR can be managed medically with periodic imaging to detect any increase in regurgitant severity. In some patients with moderate to severe or severe PVR, medical therapy may be possible using guideline-directed medical therapy for heart failure or haemolytic anaemia. When intervention is needed, surgical aortic valve replacement (SAVR) may be considered, but many of these patients may be high risk for surgery or prefer to avoid surgical intervention. Transcatheter options include a vascular occluder device, a redo TAVI with placement of a second transcatheter valve (TAV-in-TAV), or balloon dilation of the initial TAVI valve.

Showing 1 to 10 of 18 Articles

Previous 1 2 Next

Articles per page

Browse All Journals

Related Journals:

Arteriosclerosis, Thrombosis, and Vascular Biology Heart Nature Reviews Cardiology European Journal of Heart Failure Journal of the American Heart Association Heart Failure Reviews Current Opinion in Cardiology JAMA Cardiology Current Atherosclerosis Reports Angiology

Kaluzna-Oleksy, Marta;

Gilard, Martine;

Morice, Marie Claude;

Barbato, Emanuele;

Dudek, Dariusz;

Chieffo, Alaide

2023 European Heart Journal

doi: 10.1093/eurheartj/ehad053pmid: 36881724

Graphical AbstractGraphical AbstractProposal of a point-by-point solution to each of the barriers described.

2023 European Heart Journal

doi: 10.1093/eurheartj/ehad054pmid: 36790101

Since the publication of the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) Guidelines for the Management of Arterial Hypertension, several high-quality studies, including randomised, sham-controlled trials on catheter-based renal denervation (RDN) were published, confirming both the blood pressure (BP)-lowering efficacy and safety of radiofrequency and ultrasound RDN in a broad range of patients with hypertension, including resistant hypertension. A clinical consensus document by the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) on RDN in the management of hypertension was considered necessary to inform clinical practice. This expert group proposes that RDN is an adjunct treatment option in uncontrolled resistant hypertension, confirmed by ambulatory BP measurements, despite best efforts at lifestyle and pharmacological interventions. RDN may also be used in patients who are unable to tolerate antihypertensive medications in the long term. A shared decision-making process is a key feature and preferably includes a patient who is well informed on the benefits and limitations of the procedure. The decision-making process should take (i) the patient’s global cardiovascular (CV) risk and/or (ii) the presence of hypertension-mediated organ damage or CV complications into account. Multidisciplinary hypertension teams involving hypertension experts and interventionalists evaluate the indication and facilitate the RDN procedure. Interventionalists require expertise in renal interventions and specific training in RDN procedures. Centres performing these procedures require the skills and resources to deal with potential complications. Future research is needed to address open questions and investigate the impact of BP-lowering with RDN on clinical outcomes and potential clinical indications beyond hypertension.

Franco, Luis Nombela;

2023 European Heart Journal

doi: 10.1093/eurheartj/ehad146pmid: 36883599

AimsParavalvular regurgitation (PVR) after transcatheter aortic valve implantation (TAVI) is associated with increased morbidity and mortality. The effect of transcatheter interventions to treat PVR after the index TAVI was investigated.Methods and resultsA registry of consecutive patients who underwent transcatheter intervention for ≥ moderate PVR after the index TAVI at 22 centers. The principal outcomes were residual aortic regurgitation (AR) and mortality at 1 year after PVR treatment. A total of 201 patients were identified: 87 (43%) underwent redo-TAVI, 79 (39%) plug closure, and 35 (18%) balloon valvuloplasty. Median TAVI-to-re-intervention time was 207 (35; 765) days. The failed valve was self-expanding in 129 (63.9%) patients. The most frequent devices utilized were a Sapien 3 valve for redo-TAVI (55, 64%), an AVP II as plug (33, 42%), and a True balloon for valvuloplasty (20, 56%). At 30 days, AR ≥ moderate persisted in 33 (17.4%) patients: 8 (9.9%) after redo-TAVI, 18 (25.9%) after plug, and 7 (21.9%) after valvuloplasty (P = 0.036). Overall mortality was 10 (5.0%) at 30 days and 29 (14.4%) at 1 year: 0, 8 (10.1%), and 2 (5.7%) at 30 days (P = 0.010) and 11 (12.6%), 14 (17.7%), and 4 (11.4%) at 1 year (P = 0.418), after redo-TAVI, plug, and valvuloplasty, respectively. Regardless of treatment strategy, patients in whom AR was reduced to ≤ mild had lower mortality at 1 year compared with those with AR persisting ≥ moderate [11 (8.0%) vs. 6 (21.4%); P = 0.007].ConclusionThis study describes the efficacy of transcatheter treatments for PVR after TAVI. Patients in whom PVR was successfully reduced had better prognosis. The selection of patients and the optimal PVR treatment modality require further investigation.